FrancophonIA/ELRC3.0 huggingface dataset:
English: There is currently no evidence that gadolinium deposition in the brain has caused any harm to patients; however EMA has recommended restrictions and suspensions for some intravenous linear agents in order to prevent any risks that could potentially be associated with gadolinium brain deposition.
Estonian: Praegu ei ole tõendeid, kas gadoliiniumi ladestumine ajus on tekitanud kahju patsientidele; sellegipoolest on EMA soovitanud kohaldada teatud intravenoossete lineaarsete kontrastainete korral piiranguid ja müügilubade peatamist, et ennetada mis tahes riske, mida võib põhjustada gadoliiniumi ladestumine ajus.
English: On 20 July 2017, the European Medicines Agency (EMA) concluded its review of gadolinium contrast agents, confirming recommendations to restrict the use of some linear gadolinium agents used in MRI body scans and to suspend the authorisations of others.
Estonian: 20. juulil 2017 lõpetas Euroopa Ravimiamet gadoliiniumipõhiste kontrastainete läbivaatamise, kinnitades soovitused piirata mõne lineaarse kontrastaine kasutamist organismi magnetresonantstomograafia uuringutes ja peatada teiste müügiluba.
English: OptiMARK (gadoversetamide) is the only gadolinium contrast agent that was authorised centrally via EMA in the EU.
Estonian: OptiMARK (gadoversetamiid) on ainus gadoliiniumipõhine kontrastaine, mille müügiluba Euroopa Liidus anti tsentraalselt Euroopa Ravimiameti kaudu.
English: The suspensions or restrictions on linear agents can be lifted if the companies concerned provide evidence of new benefits in an identified patient group that outweigh the risk of brain deposition or if the companies can modify their products so they do not release gadolinium significantly or cause its retention in tissues.
Estonian: Lineaarsete kontrastainete müügilubade peatamine või piirangud võidakse tühistada, kui asjaomased ettevõtted esitavad tõendid nende ühendite täiendava kasulikkuse kohta kindlas patsiendirühmas ja kasulikkus on suurem kui gadoliiniumi ajus ladestumise risk või kui need ettevõtted muudavad oma tooteid nii, et neist ei vabane oluliselt gadoliiniumi ja need põhjusta gadoliiniumi püsimist kudedes.
English: • Gadolinium contrast agents are essential for diagnosing a wide range of life-threatening and debilitating diseases.
Estonian: • Gadoliiniumipõhised kontrastained on keskse tähtsusega paljude eluohtlike ja invaliidistavate haiguste diagnoosimisel.
English: • If you need a scan with a gadolinium contrast agent to help in your treatment, your doctor will use the lowest dose required for a clear image.
Estonian: • Kui teie ravi toetamiseks on vaja uuringut gadoliiniumipõhise kontrastainega, kasutab arst kõige väiksemat selge kujutise saamiseks vajalikku annust.
English: • It is known that small amounts of gadolinium may remain in the brain after a scan with these agents, although there is currently no evidence that these small amounts cause any harm.
Estonian: • Teadaolevalt võib pärast nende kontrastainetega tehtud uuringuid väike kogus gadoliiniumi ajus säilida, kuigi praegu ei ole tõendeid, et see väike kogus on patsiendile mingil viisil kahjulik.
English: These body scans rely on the magnetic fields produced by water molecules in the body.
Estonian: Need uuringud põhinevad organismi veemolekulide tekitatavatel magnetväljadel.
English: This review covers agents containing the following active substances: gadobenic acid, gadobutrol, gadodiamide, gadopentetic acid, gadoteric acid, gadoteridol, gadoversetamide and gadoxetic acid.
Estonian: Selles menetluses vaadati läbi järgmisi toimeaineid sisaldavad kontrastained: gadobeenhape, gadobutrool, gadodiamiid, gadopenteethape, gadoteerhape, gadoteridool, gadoversetamiid ja gadokseethape.
English: Gadolinium contrast agents are used as contrast enhancers to improve image quality with magnetic resonance scans.
Estonian: Gadoliiniumipõhiseid kontrastaineid kasutatakse kontrasti tugevdina kujutise kvaliteedi parandamiseks magnetresonantstomograafia uuringutes.
English: • As a precaution, doctors will stop using some contrast agents given into the vein while some others will only be used when other agents are not suitable (e.g. for liver scans).
Estonian: • Ettevaatusabinõuna lõpetavad arstid teatud veenisiseselt manustatavate kontrastainete kasutamise ning mõnd kontrastainet kasutatakse edaspidi üksnes juhul, kui teised kontrastained ei sobi (nt maksauuringutes).
English: • Healthcare professionals in the EU will be sent a letter with information about EMA's review of gadolinium contrast agents.
Estonian: • Euroopa Liidus tegutsevatele tervishoiutöötajatele saadetakse kiri teabega ameti läbivaatamismenetluse kohta seoses gadoliiniumipõhiste kontrastainetega.
English: These products can continue to be used in their current indications but in the lowest doses that enhance images sufficiently and only when unenhanced body scans are not suitable.
Estonian: Neid kontrastaineid võib jätkuvalt kasutada praegustel näidustustel, kuid väikseimas kontrasteerimiseks piisavas annuses ja üksnes juhul, kui kontrasteerimata uuringud ei sobi.
English: • Healthcare professionals should use gadolinium contrast agents only when essential diagnostic information cannot be obtained with unenhanced scans.
Estonian: • Tervishoiutöötajad tohivad gadoliiniumipõhiseid kontrastaineid kasutada üksnes juhul, kui kontrasteerimata uuringutega ei ole võimalik saada esmatähtsat diagnostilist teavet.
English: linear (intra-articular)
Estonian: lineaarne kontrastaine (intraartikulaarne)
English: All other intravenous linear products (gadodiamide, gadopentetic acid and gadoversetamide) should be suspended in the EU.
Estonian: Kõikide teiste intravenoossete lineaarsete kontrastainete (gadodiamiid, gadopenteethape ja gadoversetamiid) müügiload tuleb Euroopa Liidus peatada.
English: • Two intravenous linear agents - gadoxetic acid and gadobenic acid - remain available as these agents undergo hepatic uptake, and can be used for imaging poorly vascularised hepatic lesions, especially in delayed phase imaging, that cannot be adequately studied with other agents.
Estonian: • Kahe intravenoosse lineaarse kontrastaine - gadokseethape ja gadobeenhape - müügiload säilitatakse, sest need ained kogunevad maksa ja nende abil on võimalik visualiseerida halvasti vaskulariseeritud maksakahjustusi (eriti hilisfaasi piltuuringutes), mida ei saa teiste kontrastainetega piisaval määral uurida.
English: • Gadolinium deposition in the brain has been confirmed by mass spectrometry and increases in signal intensity in brain tissue.
Estonian: • Gadoliiniumi ladestumist ajus on tõendatud massispektromeetria meetodil ja ajukoes tuvastatud suurenenud signaalitugevuse põhjal.
English: • Data on stability, as well as in vitro and non-clinical studies, show that linear gadolinium agents release gadolinium from the ligand molecules to a greater extent than macrocyclic agents.
Estonian: • In vitro ja mittekliinilistes uuringutes saadud stabiilsusandmed tõendavad, et gadoliiniumipõhiste lineaarsete kontrastainete korral vabaneb gadoliinium ligandi molekulide küljest rohkem kui makrotsükliliste kontrastainete korral.
English: The recommendations - confirmed by EMA's Committee for Medicinal Products for Human Use (CHMP) - followed a review that found that gadolinium deposition occurs in brain tissues following use of gadolinium contrast agents.
Estonian: Ameti inimravimite komitee kinnitatud soovitused põhinevad läbivaatamismenetlusel, milles leiti, et pärast gadoliiniumipõhiste kontrastainete kasutamist ladestub gadoliinium ajukoes.
English: • The marketing authorisations for the intravenous linear agents gadodiamide and gadoversetamide, as well as the intravenous formulation of the linear agent gadopentetic acid, are now suspended in the EU.
Estonian: • Intravenoossete lineaarsete kontrastainete gadodiamiidi ja gadoversetamiidi, samuti lineaarse kontrastaine gadopenteethappe intravenoosse ravimvormi müügiload on nüüd Euroopa Liidus peatatud.
English: EMA's scientific review of gadolinium deposition in brain and other tissues is now concluded.
Estonian: Euroopa Ravimiameti teaduslik läbivaatamine seoses gadoliiniumi ladestumisega ajukoes ja teistes kudedes on nüüd lõpetatud.
English: Optimark (gadoversetamide)
Estonian: Optimark (gadoversetamiid)
English: Another class of gadolinium agents known as macrocyclic agents (gadobutrol, gadoteric acid and gadoteridol) are more stable and have a lower propensity to release gadolinium than linear agents.
Estonian: Teised gadoliiniumipõhised kontrastained, nimelt makrotsüklilised kontrastained (gadobutrool, gadoteerhape ja gadoteridool), on stabiilsemad ja gadoliinium ei vabane neist nii kergesti kui lineaarsetest kontrastainetest.
English: Most gadolinium-containing contrast agents have been authorised nationally in the EU.
Estonian: Enamik gadoliiniumi sisaldavaid kontrastaineid on Euroopa Liidus müügiloa saanud riiklike menetluste teel.
English: Omniscan (gadodiamide)
Estonian: Omniscan (gadodiamiid)
English: (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's final opinion.
Estonian: Ravimiohutuse riskihindamise komitee lõplikud soovitused saadeti seejärel inimravimite komiteele, kes vastutab inimravimitega seotud küsimuste eest ja kes võttis vastu Euroopa Ravimiameti lõpliku arvamuse.
English: Once injected, gadolinium interacts with the water molecules.
Estonian: Süstitud gadoliinium reageerib veemolekulidega.
English: The intravenous linear agents gadoxetic acid and gadobenic acid can continue to be used for liver scans because they are taken up in the liver and meet an important diagnostic need.
Estonian: Intravenoosseid lineaarseid kontrastaineid gadokseethapet ja gadobeenhapet võib ka edaspidi kasutada maksauuringutes, sest need kogunevad maksa ja on suure diagnostilise tähtsusega.
English: • Gadolinium contrast agents are given to patients during body scans to help obtain a clear image of the inside of the body.
Estonian: • Gadoliiniumipõhiseid kontrastaineid manustatakse organismi magnetresonantstomograafia uuringutes patsientidele selleks, et selgemalt visualiseerida organismi sisemust.
English: • No adverse neurological effects, such as cognitive or movement disorders, have been attributed to gadolinium deposition in the brain with any gadolinium agents.
Estonian: • Gadoliiniumi ajus ladestumisest tingitud kahjulikke neuroloogilisi toimeid (nt kognitiivsed häired või liikumishäired) ei ole ühegi gadoliiniumi kontrastaine korral täheldatud.
English: Artirem / Dotarem (gadoteric acid) macrocyclic (intra-articular) maintain Gadovist (gadobutrol)
Estonian: Artirem / Dotarem (gadoteerhape) makrotsükliline kontrastaine (intraartikulaarne)
English: Prohance (gadoteridol)
Estonian: Prohance (gadoteridool)
English: In addition, gadopentetic acid given intra-articularly (into the joint) can continue to be used for joint scans because the dose of gadolinium used for joint injections is very low.
Estonian: Peale selle võib jätkata intraartikulaarselt (liigesesse) manustatava gadopenteethappe kasutamist liigeseuuringutes, kuna liigesesse süstitava gadoliiniumi annus on väga väike.
English: • All macrocyclic agents reviewed - gadobutrol, gadoteric acid and gadoteridol - also remain available.
Estonian: • Müügiload säilitatakse ka kõikidel läbivaadatud makrotsüklilistel kontrastainetel: gadobutroolil, gadoteerhappel ja gadoteridoolil.
English: Artirem / Dotarem (gadoteric acid) macrocyclic (i.v.)
Estonian: Artirem / Dotarem (gadoteerhape) makrotsükliline kontrastaine (intravenoosne)
English: Multihance (gadobenic acid)
Estonian: Multihance (gadobeenhape)
English: • The product information for gadolinium contrast agents remaining on the EU market is being updated accordingly.
Estonian: • Gadoliiniumipõhiste kontrastainete puhul, mille müügiload Euroopa Liidu turul säilitatakse, muudetakse vastavalt ravimiteavet.
English: Recommendations conclude EMA's scientific review of gadolinium deposition in brain and other tissues
Estonian: Euroopa Ravimiameti teaduslik läbivaatamine gadoliiniumi ladestumise kohta ajukoes ja teistes kudedes lõpetati soovitustega
English: • Intra-articular formulations of the linear agent gadopentetic acid will continue to be available because the dose of gadolinium that is required for these scans is very low.
Estonian: • Lineaarse kontrastaine gadopenteethappe intraartikulaarsete ravimvormide müügiload säilitatakse, kuna nendega tehtavates uuringutes on vaja vaid väga väikest gadoliiniumiannust.
English: Primovist (gadoxetic acid)
Estonian: Primovist (gadokseethape)
English: Product
Estonian: Ravim
English: EMA/CHMP/380101/2016 EMEA/H/C/004207
Estonian: EMA/CHMP/380101/2016 EMA/H/C/004207
English: The full EPAR for Bortezomib Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Bortezomib Hospira kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Bortezomib Hospira?
Estonian: Mis meetmed võetakse, et tagada Bortezomib Hospira ohutu ja efektiivne kasutamine?
English: It blocks proteasome, which is a system in cells that breaks down proteins that are no longer needed.
Estonian: Bortesomiib blokeerib proteasoomi ehk rakkudes oleva süsteemi, mis lagundab valke, kui neid enam ei vajata.
English: • adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, blood stem-cell transplantation.
Estonian: • täiskasvanud, kelle haigus süveneb pärast vähemalt üht muud raviskeemi ja kellele on vereloome tüvirakke juba siiratud või seda ei saa teha.
English: The company that markets Bortezomib Hospira will supply educational material to healthcare professionals on making up and giving the injection, calculating the dose, and prescribing and giving the correct treatment for patients receiving blood stem-cell transplantation.
Estonian: Bortezomib Hospirat turustav ettevõte annab tervishoiutöötajatele õppematerjalid, kuidas valmistada ravimit ja teha süste, kuidas arvutada õiget annust ning määrata ja tagada korrektne ravi patsientidele, kellele tehakse vereloome tüvirakkude siirdamist.
English: No additional studies were needed as Bortezomib Hospira is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Velcade.
Estonian: Lisauuringuid ei olnud vaja, sest Bortezomib Hospira on süstina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Velcade.
English: The Committee recommended that Bortezomib Hospira be approved for use in the EU.
Estonian: Komitee soovitas ravimi Bortezomib Hospira kasutamise Euroopa Liidus heaks kiita.
English: Bortezomib Hospira bortezomib
Estonian: Bortezomib Hospira bortesomiib
English: Doses of Bortezomib Hospira are given with rest periods between doses, in treatment cycles of three to six weeks depending on whether Bortezomib Hospira is given alone or in combination with other medicines.
Estonian: Bortezomib Hospirat manustatakse järk-järgult, jättes annuste vahele puhkeperioodi, nii et ravikuurid kestavad 3-6 nädalat sõltuvalt sellest, kas Bortezomib Hospirat kasutatakse ainuravimina või koos muude ravimitega.
English: Bortezomib Hospira must not be given by other routes.
Estonian: Bortezomib Hospirat ei tohi manustada teistel viisidel.
English: Because Bortezomib Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Bortezomib Hospira on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This means that Bortezomib Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU) called Velcade.
Estonian: See tähendab, et Bortezomib Hospira on sarnane võrdlusravimiga Velcade, millel juba on Euroopa Liidus müügiluba.
English: Bortezomib Hospira is a cancer medicine used to treat multiple myeloma, a blood cancer, in the following groups of patients:
Estonian: Bortezomib Hospira on vähiravim, mida kasutatakse hulgimüeloomi (teatud verevähi) raviks järgmistel patsiendirühmadel:
English: What is Bortezomib Hospira and what is it used for?
Estonian: Mis on Bortezomib Hospira ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Bortezomib Hospira.
Estonian: See on ravimi Bortezomib Hospira Euroopa avaliku hindamisaruande kokkuvõte.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Bortezomib Hospira has been shown to be comparable to Velcade.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Bortezomib Hospira sarnane toime ravimiga Velcade.
English: Other information about Bortezomib Hospira
Estonian: Muu teave Bortezomib Hospira kohta
English: At least 72 hours must pass between two doses of Bortezomib Hospira.
Estonian: Bortezomib Hospira kahe annuse manustamise vaheline aeg peab olema vähemalt 72 tundi.
English: • previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation.
Estonian: • varem ravimata täiskasvanud, kellele hakatakse tegema suureannuselist keemiaravi, millele järgneb vereloome tüvirakkude siirdamine.
English: For practical information about using Bortezomib Hospira, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Bortezomib Hospira kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It is not intended to provide practical advice on how to use Bortezomib Hospira.
Estonian: Hindamisaruandes ei anta Bortezomib Hospira kasutamise praktilisi nõuandeid.
English: • previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation.
Estonian: • varem ravimata täiskasvanud, kellel ei saa kasutada suure annusega keemiaravi koos vereloome tüvirakkude siirdamisega.
English: Bortezomib Hospira is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation.
Estonian: Bortezomib Hospirat kasutatakse ka teist tüüpi verevähi, mantelrakulise lümfoomi raviks varem ravimata täiskasvanutel, kellele ei saa siirata vereloome tüvirakke.
English: Cancer cells are more sensitive than normal cells to the effects of proteasome inhibitors like bortezomib.
Estonian: Vähirakud on bortesomiibisarnaste proteasoomiinhibiitorite suhtes palju tundlikumad kui terved rakud.
English: In these patients, Bortezomib Hospira is used in combination with melphalan and prednisone;
Estonian: Bortezomib Hospirat kasutatakse neil patsientidel koos melfalaani ja prednisooniga;
English: Bortezomib Hospira is available in vials as a 3.5 mg powder to be made up into a solution for injection into a vein or under the skin.
Estonian: Bortezomib Hospirat turustatakse 3,5 mg süstelahuse pulbrit sisaldavates viaalides; pulbrist valmistatakse veeni või naha alla süstitav lahus.
English: For more information about treatment with Bortezomib Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Bortezomib Hospiraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Bortezomib Hospira is a ‘generic medicine'.
Estonian: Bortezomib Hospira on geneeriline ravim.
English: For mantle cell lymphoma, Bortezomib Hospira is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
Estonian: Mantelrakulise lümfoomi ravis kasutatakse Bortezomib Hospirat koos rituksimaabi, tsüklofosfamiidi, doksorubitsiini ja prednisooniga.
English: The medicine can only be obtained with a prescription and treatment should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy.
Estonian: Bortezomib Hospira on retseptiravim ning ravi peab algama ja toimuma vähi keemiaravis kogenud arsti järelevalve all.
English: Why is Bortezomib Hospira approved?
Estonian: Miks Bortezomib Hospira heaks kiideti?
English: Therefore, the CHMP's view was that, as for Velcade, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Velcade korral, ületab Bortezomib Hospira kasulikkus sellega kaasnevad riskid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bortezomib Hospira have also been included in the summary of product characteristics and the package leaflet.
Estonian: Bortezomib Hospira ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati ravimi ohutu ja tõhusa kasutamise teave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The active substance in Bortezomib Hospira, bortezomib, is a proteasome inhibitor.
Estonian: Bortezomib Hospira toimeaine bortesomiib on proteasoomiinhibiitor.
English: Bortezomib Hospira contains the active substance bortezomib.
Estonian: Bortezomib Hospira sisaldab toimeainena bortesomiibi.
English: In this group of patients, Bortezomib Hospira is used in combination with dexamethasone, or with dexamethasone plus thalidomide.
Estonian: Selles patsiendirühmas kasutatakse Bortezomib Hospirat koos deksametasooniga või koos deksametasooni ja talidomiidiga.
English: How is Bortezomib Hospira used?
Estonian: Kuidas Bortezomib Hospirat kasutatakse?
English: How has Bortezomib Hospira been studied?
Estonian: Kuidas Bortezomib Hospirat uuriti?
English: How does Bortezomib Hospira work?
Estonian: Kuidas Bortezomib Hospira toimib?
English: Bortezomib Hospira is either used on its own in these patients or in combination with pegylated liposomal doxorubicin or dexamethasone;
Estonian: Neil patsientidel kasutatakse Bortezomib Hospirat kas ainuravimina või koos pegüleeritud liposomaalse doksorubitsiini või deksametasooniga;
English: For more information on the use of Bortezomib Hospira see the summary of product characteristics (also part of the EPAR).
Estonian: Lisateave Bortezomib Hospira kohta on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: What are the benefits and risks of Bortezomib Hospira?
Estonian: Milles seisneb Bortezomib Hospira kasulikkus ja mis riskid ravimiga kaasnevad?
English: The median follow-up duration was 33 months.
Estonian: Jälgimisaja mediaan oli 33 kuud.
English: (See picture).
Estonian: (Vt pilti).
English:  Before you start.
Estonian:  Enne kui alustate
English: Date of first authorisation: 23 September 2015
Estonian: Müügiloa esmase väljastamise kuupäev: 25. september 2015
English: (See section 6.6)
Estonian: (Vt lõik 4.4).
English: • Wash your hands with soap and water and dry with a towel.
Estonian: • Peske käed seebi ja veega ning kuivatage rätikuga.
English: With long-term treatment, efficacy was sustained over the duration of the studies (up to 2 years).
Estonian: Efektiivsus püsis pikaajalisel ravil kogu uuringute kestuse vältel (kuni 2 aastat).
English:  Look at the window.
Estonian:  Vaadake akent
English: • If the window does not turn completely yellow, call sanofi-aventis for help.
Estonian: • Kui aken ei muutu üleni kollaseks, helistage abi saamiseks sanofi-aventisesse.
English: A total of 99.5% of patients were followed for survival until the end of the trial.
Estonian: 99,5% patsientide elulemust jälgiti kuni uuringu lõpuni.
English: LONG TERM study
Estonian: LONG TERM uuring
English: • Make sure you can see the window.
Estonian: • Veenduge, et aken on teile nähtav.
English: Not all presentations and pack sizes may be marketed.
Estonian: Kõik pakendid ja pakendi suurused ei pruugi olla müügil.
English: ALTERNATIVE study
Estonian: ALTERNATIVE uuring
English: Release the button immediately
Estonian: Vabastage nupp kohe
English: HIGH FH study
Estonian: HIGH FH uuring
English: Consequently, the frequency of these adverse events is qualified as "not known".
Estonian: Sellest tulenevalt on nende kõrvaltoimete sagedusmääratlus „Teadmata“.